Avalo Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Avalo Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2015 to Q3 2024.
  • Avalo Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $1.85M, a 93.9% increase year-over-year.
  • Avalo Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $3.72M, a 5.05% increase year-over-year.
  • Avalo Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3.48M, a 54% decline from 2022.
  • Avalo Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7.55M, a 7.56% decline from 2021.
  • Avalo Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $8.17M, a 20.4% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $3.72M $1.85M +$895K +93.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $2.83M $471K -$422K -47.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $3.25M $629K -$226K -26.4% Jan 1, 2024 Mar 31, 2024 10-Q/A 2024-07-11
Q4 2023 $3.48M $774K -$68K -8.08% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-29
Q3 2023 $3.54M $953K +$222K +30.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $3.32M $893K +$224K +33.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $3.1M $855K -$4.46M -83.9% Jan 1, 2023 Mar 31, 2023 10-Q/A 2024-07-11
Q4 2022 $7.55M $842K -$1.05M -55.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 $8.6M $731K -$1.03M -58.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $9.63M $669K -$2.41M -78.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $12M $5.31M +$3.86M +267% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $8.17M $1.89M +$457K +31.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-29
Q3 2021 $7.72M $1.76M +$310K +21.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $7.41M $3.07M +$288K +10.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $7.12M $1.45M +$331K +29.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $6.79M $1.44M +$914K +176% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-02
Q3 2020 $5.87M $1.45M +$629K +76.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $5.24M $2.79M +$2.26M +429% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-02
Q1 2020 $2.98M $1.12M +$520K +87.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $2.46M $521K -$114K -18% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-08
Q3 2019 $2.58M $819K -$126K -13.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $2.7M $527K -$81.7K -13.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $2.78M $597K +$354K +146% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $2.43M $635K +$330K +108% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 $2.1M $945K +$681K +258% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $1.42M $608K +$353K +138% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $1.07M $243K -$89.4K -26.9% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $1.16M $305K +$49.3K +19.3% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-18
Q3 2017 $1.11M $264K -$23.5K -8.18% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $1.13M $256K +$41.6K +19.4% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $1.09M $332K -$605K -64.6% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-11
Q4 2016 $1.69M $256K +$182K +248% Oct 1, 2016 Dec 31, 2016 10-K 2018-04-02
Q3 2016 $1.51M $288K +$259K +892% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $1.25M $214K -$27.9K -11.5% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 $1.28M $937K +$887K +1768% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q4 2015 $395K $73.5K Oct 1, 2015 Dec 31, 2015 10-K 2018-04-02
Q3 2015 $29K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-08
Q2 2015 $242K Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-15
Q1 2015 $50.2K Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.